Vertex Pharmaceuticals, Inc. (VRTX) Misses Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $510.92 -0.79%
EPS Growth %: -0.6%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -0.6%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.13, $0.06 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $336 million versus the consensus estimate of $377.14 million.Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
- Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
